Tirzepatide, the active component in the prescription drug Mounjaro 5 mg, has garnered significant attention in recent years for its efficacy in managing form 2 diabetes. Approved by the U.S. Food and Medicine Government (FDA) for this function, tirzepatide works by acting as a double agonist for the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)...